Journal
NATURE MEDICINE
Volume 29, Issue 1, Pages 39-40Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41591-022-02119-0
Keywords
-
Ask authors/readers for more resources
The ongoing CIRCULATE-Japan trial is investigating the role of ctDNA-based molecular residual disease testing in patients with resectable colorectal cancer after surgery. An interim analysis of GALAXY, a prospective observational arm, confirms ctDNA as a prognostic and predictive biomarker.
The large, ongoing CIRCULATE-Japan trial is investigating the role of circulating tumor DNA (ctDNA)-based molecular residual disease testing in patients with resectable colorectal cancer after radical surgery. An interim analysis of GALAXY, a prospective, observational arm of CIRCULATE-Japan, establishes ctDNA as a prognostic and predictive biomarker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
